SCHEDULE: ARK Investment Management Updates Stake in Twist Bioscience

ARK Investment Management LLC and Catherine D. Wood have filed an amendment to their Schedule 13G, reporting a combined beneficial ownership of 5.11% in Twist Bioscience Corp.

Summary

• This filing is an Amendment No. 10 to Schedule 13G, reporting changes in beneficial ownership of Twist Bioscience Corp. common stock.
• ARK Investment Management LLC and Catherine D. Wood are jointly filing this amendment.
• The total aggregate amount beneficially owned by both ARK Investment Management LLC and Catherine D. Wood is 3,385,850 shares.
• This represents 5.11% of the class of securities.
• The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a routine update on beneficial ownership rather than a significant strategic shift or financial performance announcement.

Positives

• The filing confirms a stable, significant ownership stake of 5.11% by ARK Investment Management and Catherine D. Wood, suggesting continued confidence in Twist Bioscience.
• The joint filing indicates a coordinated approach to reporting beneficial ownership, which can be seen as a sign of transparency.

Negatives

• The filing does not contain any new financial performance data or strategic initiatives, limiting its immediate impact on valuation.

Risks

• While not explicitly stated as a risk in this filing, any significant changes in ARK's investment strategy or market sentiment towards Twist Bioscience could impact the ownership stake.
• Regulatory changes affecting beneficial ownership reporting could pose a future challenge.

Future Outlook

This filing is an amendment to a Schedule 13G and does not contain forward-looking statements or specific future guidance from the company itself. It pertains to the reporting of ownership by ARK Investment Management and Catherine D. Wood.

Management Comments

• "ARK Investment Management LLC and Catherine D. Wood do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file an Amendment No. 10 on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Amendment No. 10 on Schedule 13G shall be filed on behalf of each of them."
• "I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect..."

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure under SEC rules for significant beneficial ownership. ARK Investment Management is known for its active management and focus on disruptive innovation, and their continued reporting on Twist Bioscience indicates ongoing interest in the synthetic biology sector.

Stakeholder Impact

• Shareholders: The filing confirms a significant and stable ownership by ARK, which may be viewed positively by some investors as a sign of institutional support.
• Management: The filing is a routine disclosure and does not directly impact management operations, but it confirms ARK's passive intent regarding control.

Next Steps

• ARK Investment Management and Catherine D. Wood will continue to report any material changes in their beneficial ownership of Twist Bioscience Corp. in accordance with SEC regulations.

Key Dates

Keywords

Twist Bioscience, ARK Investment Management, Catherine Wood, Schedule 13G, Beneficial Ownership, Amendment, Common Stock, Investment Management